Moderna Expands mRNA Platform with In Vivo CAR-T Therapy

What happened

At its Science Day event, Moderna outlined its three-horizon development strategy spanning late-stage commercialised products, emerging clinical modalities, and future candidates. The company introduced mRNA-6007, its first in vivo CAR-T programme targeting CD7 on T cells for B-cell-mediated autoimmune diseases including lupus. Unlike traditional ex vivo CAR-T therapies requiring complex manufacturing and lymphodepletion, Moderna's approach uses lipid nanoparticles to deliver mRNA directly to CD4 and CD8 T cells and natural killer cells, enabling off-the-shelf treatment. The company is completing IND-enabling studies and conducting regulatory engagements ahead of clinical trials starting in 2026. Moderna also highlighted progress in T-cell engagers, with mRNA-4106 in Phase I for solid tumours, mRNA-4200 advancing into Phase I combination studies with Keytruda, and mRNA-4194 in Phase I/II trials for metastatic melanoma and non-small cell lung cancer.

Why it matters

The in vivo CAR-T platform represents a potentially transformative approach to autoimmune disease treatment by simplifying manufacturing and eliminating the need for patient-specific cell therapy production. Moderna emphasised its unique manufacturing scale advantage for mRNA-LNP technology, positioning the company to address large commercial opportunities in autoimmune conditions where confirmatory trials require substantial patient populations. The broadening pipeline across oncology and rare diseases demonstrates Moderna's efforts to diversify revenue beyond its four approved infectious disease vaccines while leveraging its core mRNA expertise. Success with the sentinel mRNA-6007 programme could unlock additional applications in oncology and T-cell reprogramming.

Bigger picture

Moderna's strategy reflects broader industry momentum around CAR-T therapies for autoimmune diseases, following compelling clinical outcomes with ex vivo CD19-directed treatments in lupus patients. The company is balancing near-term infectious disease vaccine revenue with long-term innovation in therapeutic modalities, responding to political pressures affecting vaccine markets. By targeting autoimmune diseases first rather than oncology for its in vivo CAR-T platform, Moderna is prioritising lower biology risk in a therapeutic area where its manufacturing scalability provides competitive advantage. The pipeline expansion across Horizon 2 and Horizon 3 programmes demonstrates ongoing investment in research and development to sustain growth beyond current commercialised products.

What to watch

Key milestones include the 2026 clinical trial start for mRNA-6007 in B-cell-mediated autoimmune conditions and regulatory feedback from pre-submission health authority engagements. Investors should monitor Phase I/II data readouts for oncology T-cell engagers, particularly mRNA-4194 in metastatic melanoma and NSCLC, and advancement of mRNA-4200 into Keytruda combination studies. Progress on late-stage candidates including intismeran autogene therapy and the propionic acidemia therapeutic will signal near-term commercial pipeline development. Watch for proof-of-concept data validating the in vivo CAR-T approach and announcements of follow-on programmes in oncology or T-cell reprogramming.